Biogen Inc. and Vanqua Bio Inc. have announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical oral C5aR1 antagonist with the potential to address a broad range of inflammatory disorders.
SVF Vaccines AB, a portfolio company of Karolinska Development AB, has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B (HBV) and D viruses (HDV).
Neumora Therapeutics Inc. has reported preclinical data for NMRA-215, a brain-penetrant, oral NLRP3 inhibitor in development for obesity, suggesting potential utility as a monotherapy as well as in combination with a GLP-1 agonist.
Cancer of the uterus is the most common gynecological malignancy in the U.S., with over 60,000 diagnoses per year, where incidence and mortality have increased through the years. About 30%-40% of patients with high-grade disease harbor mutations in the PPP2R1A gene, which encodes the primary subunit of protein phosphatase 2A, with hotspots being P179R and S256F.
At this year’s AACR-NCI-EORTC conference, several presentations brought to light new ways to tackle the treatment of genomically unstable cancers. Genomically unstable cancers can be treated by exploiting their repair dependencies, inducing catastrophic DNA damage, or harnessing immune responses to instability.
Hefei Institutes of Physical Sciences has synthesized new pyrazoleamide compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, Crohn’s, Graves, Parkinson’s disease, ischemia, sepsis, multiple sclerosis and HIV infection.
Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Park City Bio LLC has prepared and tested new serotonin receptor agonists reported to be useful for the treatment of pain, inflammation, psychiatric and neurological disorders.
Gilead Sciences Inc. has reported new compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
RSS
